SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-065188
Filing Date
2024-08-05
Accepted
2024-08-05 16:10:13
Documents
13
Period of Report
2024-08-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021054901-8k_elevai.htm   iXBRL 8-K 23720
  Complete submission text file 0001213900-24-065188.txt   198593

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE elab-20240801.xsd EX-101.SCH 3033
3 XBRL LABEL FILE elab-20240801_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE elab-20240801_pre.xml EX-101.PRE 22371
15 EXTRACTED XBRL INSTANCE DOCUMENT ea021054901-8k_elevai_htm.xml XML 3803
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241174842
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)